Cancer drug developer Heat Biologics adds shares to IPO

Hoping to capture some of the new excitement for select biotech IPOs, Heat Biologics bumped the size of the maiden offering today to 2.3 million shares. At the top of its $10 to $12 range, the offering could raise more than $27 million. The Chapel Hill, NC-based cancer and infectious disease drug developer was founded 5 years ago, develops new immunotherapies and will trade as HTBX. This will be the 23rd biotech IPO of the year. Story